GRAFT POLYMER UK LS -001 (J4I) - Total Assets
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) holds total assets worth €7.58 Million EUR (≈ $8.87 Million USD) as of November 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GRAFT POLYMER UK LS -001 - Total Assets Trend (2022–2026)
This chart illustrates how GRAFT POLYMER UK LS -001's total assets have evolved over time, based on quarterly financial data. Also see GRAFT POLYMER UK LS -001 market capitalisation for the company's overall valuation and market capitalisation.
GRAFT POLYMER UK LS -001 - Asset Composition Analysis
Current Asset Composition (May 2026)
GRAFT POLYMER UK LS -001's total assets of €7.58 Million consist of 25.3% current assets and 74.7% non-current assets. Review J4I liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.7% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how GRAFT POLYMER UK LS -001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See J4I live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GRAFT POLYMER UK LS -001's current assets represent 25.3% of total assets in 2026, an increase from 23.6% in 2022.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2026, up from 19.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GRAFT POLYMER UK LS -001 Competitors by Total Assets
Key competitors of GRAFT POLYMER UK LS -001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
GRAFT POLYMER UK LS -001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.00 | 6.85 | 0.15 |
| Quick Ratio | 4.00 | 6.85 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.44 Million | €696.00K | €-413.00K |
GRAFT POLYMER UK LS -001 - Advanced Valuation Insights
This section examines the relationship between GRAFT POLYMER UK LS -001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.10 |
| Latest Market Cap to Assets Ratio | 1.04 |
| Asset Growth Rate (YoY) | 136.8% |
| Total Assets | €7.58 Million |
| Market Capitalization | $7.90 Million USD |
Valuation Analysis
Above Book Valuation: The market values GRAFT POLYMER UK LS -001's assets above their book value (1.04x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: GRAFT POLYMER UK LS -001's assets grew by 136.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GRAFT POLYMER UK LS -001 (2022–2026)
The table below shows the annual total assets of GRAFT POLYMER UK LS -001 from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-05-31 | €7.58 Million ≈ $8.87 Million |
+136.81% |
| 2025-05-31 | €3.20 Million ≈ $3.74 Million |
+31.59% |
| 2024-05-31 | €2.43 Million ≈ $2.85 Million |
-50.72% |
| 2023-05-31 | €4.94 Million ≈ $5.77 Million |
+57.80% |
| 2022-05-31 | €3.13 Million ≈ $3.66 Million |
-- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more